Organoids and Spheroids Market Expected to Reach $1.2 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Organoids and Spheroids Market," The Organoids and Spheroids Market size was valued at $516.56 million in 2021, and is estimated to reach $1.2 billion by 2031, growing at a CAGR of 8.5% from 2022 to 2031.

Organoids and spheroids are two types of 3D cell cultures. which is a cluster of biological cells grown in an artificially created environment. These biological cells are permitted to grow or interact with their surroundings in all three dimensions.

The Organoids and Spheroids Market trends are an increase in the adoption of personalized medicines, growth in investments toward R&D activities, and a shift in preference toward organoids 3D cell cultures for cancer research are the major factors that boost the Organoids and Spheroids Market growth. In addition, the rise in technological advancement in 3D spheroids technologies in developing countries such as China, Japan, and India would propel the growth of the organoids and spheroid industry. However, the high cost of implementation hampers the market growth. Conversely, the emerging healthcare market in developing countries is expected to provide a lucrative opportunity during the forecast period. 

On the basis of type, the Organoids and Spheroids Market are segmented into organoids and spheroids. In 2021, the organoids segment accounted for the largest share of the market. The dominance of this segment can be attributed to rise in the adoption of organoids in various applications such as disease modeling, pathogenesis, drug screening, and regenerative medicine.

On the basis of method, it is segmented into extracellular matrix scaffold method, spinning bioreactor method, hanging drop method, low adherent culture plate method, magnetic levitation method, and others, the extracellular matrix scaffold method segment exhibited the Organoids and Spheroids Market share in 2021, and is anticipated to lead during the forecast period.

By end user it is segmented into biotechnology and pharmaceutical industries, academic & research institutes, hospitals, and diagnostic centers, the biotechnology and pharmaceutical industries segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period, owing to increased use of organoids for biopharmaceuticals and cancer drug research are the key factors that drive the growth of the market in upcoming years.

North America accounted for a majority of the organoids and spheroid market share in 2021 and is anticipated to remain dominant during the forecast period. Owing to the presence of several pharmaceutical and biotechnology companies that use 3D culture technology in collaboration with research institutes and clinical laboratories for developing regenerative medicines and drug discovery & development.

Asia-Pacific was the second largest contributor to the market in 2021 and is expected to register the fastest CAGR during the forecast period, due to economic development and low operating costs. Moreover, the rising focus in biopharmaceutical R&D, the huge production of drugs, and the surge in the prevalence of cancer are also propelling the growth of the market in this region.

The key players that operate in the Organoids and Spheroids Industryare AMS Biotechnology Limited, ATCC, 3D Biotek LLC, 3Dnamics Inc., Cellesce Ltd., Corning Inc, DefiniGEN Ltd, Greiner AG, Hubrecht Organoid Technology, InSphero AG, Lonza, Merck KGaA, PeproTech Inc., Perkin Elmer Inc, Prellis Biologics, STEMCELL Technologies Inc. and Thermofisher Scientific Inc.

KEY FINDINGS OF THE STUDY

• By type, the organoids segment was the highest contributor to the market in 2021.
• By method, the extracellular matrix scaffold method segment was the highest contributor to the market in 2021.
• By end user, the biotechnology and pharmaceutical industries segment is projected to grow at a significant CAGR of 9.0% from 2022 to 2031.
• By region, North America garnered largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 9.5% during the review period.